Boylan carving out new investment niche for Patient Square

With $300 million raised and its first investment imminent, Patient Square Capital’s newly launched Enavate Sciences is building a team around veteran investment banker James Boylan and is already looking ahead to another fund-raise this year. Launched May 2, the firm is hoping to take advantage of a downturn that has left quality companies in a cash crunch to build a portfolio of clinical companies with narrowly focused pipelines ready for their next stage of growth.

“All of a sudden, capital is a little bit more difficult to come by, despite the fact that we’re truly in a golden age of therapeutics,” Boylan told BioCentury...